Inavolisib lengthens progression-free survival time in HER2-negative advanced breast cancer
1. In this randomized controlled trial, in patients with PIK3CA-mutated advanced breast cancer, the addition of inavolisib to a palbociclib-fulvestrant ...
Tag: Her2
AstraZeneca and Daiichi Sankyo: Enhertu significantly reduced the risk of disease progression in low and ultra-low HER2 metastatic breast cancer.
In patients with hormone-receptor (HR)-positive metastatic breast cancer and low or ultra-low levels of HER2 expression, Enhertu led to a ...
Trastuzumab Deruxtecan in Solid Tumours Harbouring HER2 Mutations
1. The objective response rate for trastuzumab deruxtecan was 29.4%. 2. Treatment-emergent adverse event grade 3 or higher was seen ...
#VisualAbstract: Pembrolizumab enhances progression-free survival in patients with HER2-positive gastro-esophageal cancer
1. Progression-free survival was significantly greater among patients in the pembrolizumab group compared to placebo (10.0 vs. 8.1 months). 2. ...
Patients with HER2-positive advanced breast cancer and pathological complete response to neoadjuvant systemic therapy may not require surgical intervention
1. In patients with pathological complete response to neoadjuvant systemic therapy, there was no tumour recurrence at 2 years 2. ...
Trastuzumab deruxtecan superior to trastuzumab emtansine in patients with metastatic HER2 breast cancer
1. Longer progression-free survival was found in patients taking trastuzumab deruxtecan compared to trastuzumab emtansine 2. Adverse events were more ...
Trastuzumab deruxtecan showed therapeutic efficacy in HER2-mutant non-small cell lung cancer
1. Patients with refractory HER2-mutant non-small cell lung cancer (NSCLC) show clinical response to trastuzumab deruxtecan. 2. Safety profiles were ...
Poziotinib reduces tumour size in patients with previously treated HER2 mutation positive non-small-cell lung cancer
1. Almost 30% of patients had an objective response rate, with roughly three-quarters experiencing a reduction in tumour size. 2. ...
Researchers test lower-toxicity chemotherapy for women with early-stage breast cancers
1. Among HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumab (Herceptin), 3 year survival without invasive disease was ...
Ramucirumab fails in HER2-negative advanced breast cancer
1. The addition of ramucirumab, a VEGF-2 receptor blocker, to docetaxel did not significantly increase progression free or overall survival in ...